GuideThe introductory offer is a starting point. Here is what to compare next.
GuideGet the transfer, refill and cancellation details clear first.
GuideWhat the product label changes about a provider comparison.
GuideFive practical details worth checking before a recurring commitment.
GuideQuestions about longer-term care deserve attention before a promotion ends.
GuideSeparate the prescription, the coverage decision and your final pharmacy bill before paying for a weight-loss program.
ResearchHow to read a GLP-1 trial: who took part, what was compared, how long it lasted and what the result cannot establish.
ResearchSeparate membership, medication and coverage assumptions before comparing a low introductory price with a full-year commitment.
ResearchWhat withdrawal research tells us—and how to prepare practical questions about records, coverage, refills and continuing care.
ResearchThe direct trial found greater average weight loss with tirzepatide. Here is the population, dose comparison and limit behind that result.
ResearchWhy a diabetes-specific trial is a better starting point than borrowing a weight-loss headline from people without diabetes.
ResearchRead the semaglutide result alongside the substantial counseling and initial dietary program supplied to both study groups.
ResearchA randomized withdrawal study shows why the starting point and the run-in population matter when reading maintenance results.
ResearchA longer weight-management trial helps distinguish sustained average results from a promise of lifelong outcomes.
ResearchThe head-to-head result, the open-label design and the treatment protocols behind this comparison.
ResearchThe 72-week trial behind many tirzepatide headlines—and why its averages are not individual targets.
ResearchWhy the lifestyle lead-in and the change of baseline matter when reading this unusually large weight-loss headline.
ResearchTwo trials measured breathing events during sleep in adults with obesity, including groups with and without baseline PAP treatment.
ResearchA diabetes-specific weight-management trial helps put the most widely advertised tirzepatide percentages in perspective.
ResearchThe prediabetes subgroup showed fewer diabetes diagnoses, but prevention over a trial period is not a lifetime guarantee.
ResearchWhy fewer combined heart-failure events should not be simplified into a claim of proven lower cardiovascular mortality.
ResearchThe cardiovascular result applies to adults with established disease; absolute event rates make the headline easier to interpret.
ResearchA kidney-outcomes trial provides evidence beyond weight loss, with a specific population, regimen and combined endpoint.
ResearchThis trial makes patient-reported symptoms and physical function central rather than treating the scale as the only meaningful outcome.
ResearchThe diabetes-specific companion trial found symptom and weight benefits, helping avoid assumptions from a different population.
ResearchAn interim phase 3 analysis improved liver histology; the result should not be confused with established long-term clinical outcomes.
ResearchA dose-finding study showed improved MASH resolution, while its size and duration limit broader conclusions.
ResearchThe oral route has its own evidence; an ingredient name alone does not make all tablets, drops and injections equivalent.
ResearchA separate oral study measured weight and physical function, with a week-64 primary endpoint inside a longer trial.
ResearchThe adolescent trial used BMI change as its primary outcome and belongs in specialist care, not adult-provider shopping.
ResearchWeight and pain improved in the trial, but a pain-score change does not establish cartilage repair or avoidance of surgery.
ResearchThe study’s glucose thresholds and treatment-period endpoint matter when interpreting a prediabetes reversal headline.
ResearchRegional eligibility criteria and a visceral-fat substudy add context that a global weight-loss headline cannot provide.
ResearchThe 44-week endpoint and inclusion of people with and without diabetes distinguish this report from other STEP studies.
ResearchA regional trial with different entry thresholds and a 52-week endpoint should retain those details when its results are quoted.
ResearchThis direct comparison used semaglutide 1 mg and a glucose endpoint; it should not be confused with the obesity-focused SURMOUNT-5 trial.
ResearchA direct dose comparison found greater average loss and more reported adverse effects; the paper is evidence, not a dose-escalation instruction.
ResearchAn imaging substudy illustrates why a scan-based fat measurement is different from a biopsy result or a clinical liver outcome.
ResearchThe kidney findings came from an additional analysis of a diabetes trial, not a dedicated kidney-outcomes experiment.
ResearchAn add-on diabetes trial answers a different question from starting a weight-management medicine on its own.
ResearchThe trial compared two ways of intensifying diabetes care, with separate glucose, weight and hypoglycemia outcomes.
ResearchA DXA substudy found reductions in both fat and lean mass; the proportions are not a direct measure of muscle strength.
ResearchA prespecified analysis extends the observation window in a cardiovascular-disease population, with different expectations from a dedicated weight-loss trial.
ResearchA prespecified composite kidney outcome adds information in cardiovascular disease, but differs from the dedicated FLOW population and endpoint.
ResearchA pooled STEP analysis examined whether gastrointestinal events explained the observed weight loss, while documenting their burden.
ResearchA post hoc analysis found no increased signal in the studied population, with important limits on psychiatric history and rare outcomes.